# Normunity

Source: https://onco.cc/companies/normunity/  
OnCo record `normunity` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Normunity develops antibody medicines that direct the immune system's T cells against tumours. Its lead, NRM-823, recognises a target found on several solid tumours but not on normal tissue, and is in an early trial.

## Summary

Normunity, located in Boston, Massachusetts, and New Haven, Connecticut, creates anti-cancer therapies at the interface of the immune system and the tumour, built on research by scientific founder Lieping Chen at Yale School of Medicine; Rachel Humphrey was founding chief executive. It announced a USD 65 million Series A in October 2022, led by Canaan with Sanofi Ventures, Taiho Ventures and Osage University Partners, and a USD 75 million Series B in January 2025, co-led by Samsara BioCapital and Enavate Sciences with Regeneron Ventures, Pfizer Ventures and YK Bioventures. Its lead, NRM-823, is a first-in-class T cell engager against what the company describes as a novel, highly tumour-specific target absent in normal systemic tissues; the first patient was dosed in November 2025 in a phase 1a/1b study (NCT07182149) alone and with checkpoint inhibition in head and neck, oesophageal, gastric and gastro-oesophageal junction cancers. Its first registered cancer trial, NCT07182149, was posted on ClinicalTrials.gov in September 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Normunity AccelCo, Inc.
- HQ: Boston, MA
- Type: biotech
- Website: https://normunity.com/

## Notes

- Founding year not stated on the pages read.
- The NRM-823 target is not disclosed.
- The registry sponsor is Normunity AccelCo, Inc.; its relationship to Normunity is assumed from the shared name and programme.
- Company news and financing releases read on 29 October 2026.

## Sources

- Official website: https://normunity.com/
- Series B release, January 2025: https://normunity.com/normunity-closes-75-million-series-b-financing-to-advance-lead-drug-program-into-the-clinic-and-broaden-pipeline-of-novel-anti-cancer-therapies-targeting-untapped-drug-mechanisms/
- First patient dosed with NRM-823, November 2025: https://normunity.com/normunity-announces-first-patient-dosed-in-phase-1-clinical-study-of-nrm-823-a-t-cell-engager-against-a-novel-tumor-specific-target-in-patients-with-solid-tumors/
- ClinicalTrials.gov: phase 1a/1b trial of NRM-823 (NCT07182149): https://clinicaltrials.gov/study/NCT07182149

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- companies: [Pfizer Ventures](https://onco.cc/companies/pfizer-ventures/), [Samsara BioCapital](https://onco.cc/companies/samsara-biocapital/), [Sanofi Ventures](https://onco.cc/companies/sanofi-ventures/)

---
JSON: https://onco.cc/api/v1/entities/normunity.json